Repare Therapeutics eyes Phase III cancer study after Mythic trial success [Yahoo! Finance]
Repare Therapeutics Inc. - Common Shares (RPTX)
Company Research
Source: Yahoo! Finance
from its Phase I gynecologic expansion trial evaluating Lunre+Camo, a combination of lunresertib and camonsertib, in patients with endometrial cancer and ovarian cancer. The MYTHIC clinical trial (NCT04855656) found that heavily pretreated patients on Lunre+Camo achieved a 25.9% overall response rate (ORR) for endometrial cancer and 37.5% in platinum-resistant ovarian cancer. Additionally, the first-in-human, global, open-label, dose-escalation trial found that nearly half of patients with gynecologic cancers maintained progression-free survival at 24 weeks compared to the current standard of care (SOC). Now the company says it is looking to pursue a registrational Phase III trial of Lunre+Camo in endometrial cancer for the second half of 2025. Lunresertib is a small molecule PKMYT1 inhibitor that treatment targets cell cycle regulation in tumours. Camonsertib is an oral inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase that selectively targets and inhibits ATR ac
Show less
Read more
Impact Snapshot
Event Time:
RPTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPTX alerts
High impacting Repare Therapeutics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
RPTX
News
- Repare Therapeutics Inc. (NASDAQ: RPTX) had its "market perform" rating re-affirmed by analysts at Lifesci Capital.MarketBeat
- Repare Therapeutics Inc. (NASDAQ: RPTX) had its price target lowered by analysts at Stifel Nicolaus from $9.00 to $4.00. They now have a "buy" rating on the stock.MarketBeat
- Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical TrialBusiness Wire
- Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial [Yahoo! Finance]Yahoo! Finance
- Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical TrialBusiness Wire
RPTX
Earnings
- 2/28/24 - Miss
RPTX
Sec Filings
- 12/12/24 - Form 8-K
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- RPTX's page on the SEC website